Vident Investment Advisory, LLC Alx Oncology Holdings Inc Transaction History

Vident Investment Advisory, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$5.89 - $19.46 $295,224 - $975,393	-50,123 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $114,045 - $184,311	8,355 Added 20.0%	50,123 $847,000
Q4 2021 Feb 14, 2022	BUY	$21.49 - $74.4 $384,305 - $1.33 Million	17,883 Added 74.87%	41,768 $898,000
Q3 2021 Nov 12, 2021	SELL	$52.51 - $80.91 $89,582 - $138,032	-1,706 Reduced 6.67%	23,885 $1.76 Million
Q2 2021 Aug 13, 2021	BUY	$52.2 - $75.23 $575,244 - $829,034	11,020 Added 75.63%	25,591 $1.4 Million
Q4 2020 Feb 08, 2021	BUY	$34.11 - $112.26 $497,016 - $1.64 Million	14,571 New	14,571 $1.26 Million

101

39.7M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $68.9M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.